Becton, Dickinson and Company(BDX) 종목 분석 — 적정가치·리스크·해자 평가

Becton, Dickinson and Company (BDX) stock price is $155.65 as of the latest market close, traded on the NYSE exchange.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems.

Becton, Dickinson and Company has a market capitalization of $56.39B, classifying it as a large-cap stock in the Healthcare sector.

Becton, Dickinson and Company operates in the Healthcare sector, specifically within the Medical Instruments & Supplies industry. It trades on the NYSE under the ticker symbol BDX.

Based on our valuation model, Becton, Dickinson and Company trades 6.4% below our fair value estimate — potentially undervalued.

• FairValueLabs Fair Value: $166.32
• Current Price: $155.65
• Valuation Zone: Watch Zone

Based on 13 Wall Street analysts, the consensus price target for Becton, Dickinson and Company is $191.46, implying upside of 23.0% from the current price.

• Analyst High Target: $225.00
• Analyst Low Target: $157.00

Note: Analyst targets are shown for reference and are not used in our valuation model.

Here are the analyst consensus growth estimates for Becton, Dickinson and Company:

• Revenue growth (current year est.): -12.3%
• EPS growth (current year est.): -13.4%
• Revenue growth (next year est.): 2.9%
• EPS growth (next year est.): 8.3%

The price-to-earnings ratio measures how much investors pay per dollar of earnings:

• Trailing P/E (last 12 months): 25.4x
• Forward P/E (next 12 months est.): 11.5x
• FairValueLabs Fair P/E: 21.6x

Becton, Dickinson and Company has a beta of 0.35, meaning it is less volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.

Becton, Dickinson and Company's balance sheet shows:

• Total Cash: $751.0M
• Total Debt: $19.54B
• Net Cash Position: $-18.79B

A positive net cash position means the company holds more cash than debt, reducing financial risk.

Becton, Dickinson and Company generated $3.11B in trailing twelve-month free cash flow (from $3.39B in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.

Yes, Becton, Dickinson and Company pays a regular dividend. Here are the key metrics:

• Dividend Yield: 2.7%
• Payout Ratio: 68.1%
• Consecutive Years Paid: 45
• 5-Year Dividend Growth: -16.4%
• FairValueLabs Safety Grade: A

Becton, Dickinson and Company's Altman Z-Score is 2.11, placing it in the gray zone (1.8–3.0) — some financial uncertainty. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.

Becton, Dickinson and Company scores 2.6/5 stars (Narrow moat · eroding) in our moat analysis:

• ROIC Stability: 2/5
• Gross Margin Trend: 3/5
• Switching Costs: 3/5

A score above 3.5 suggests meaningful pricing power and a defensible market position.

Becton, Dickinson and Company's return on equity is 7.0%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.

BDX shares can be purchased through any brokerage account that provides access to the NYSE. Common steps:

1. Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
2. Search for ticker symbol BDX
3. Place a market or limit order for your desired number of shares

This is not investment advice. Always do your own research before buying any stock.

FairValueLabs classifies Becton, Dickinson and Company as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.

The current CEO of Becton, Dickinson and Company is Mr. Thomas E. Polen Jr..

Earnings per share measures the company's profit allocated to each outstanding share:

• Trailing EPS (last 12 months): $6.12
• Forward EPS (next 12 months est.): $13.50
• Analyst consensus EPS (this year): $12.47
• Analyst consensus EPS (next year): $13.50